Osteoporosis is a syndrome of excessive skeletal fragility most often resulting from estrogen deficiency and aging. The decline of trabecular bone structure and other aspects of bone quality secondary to estrogen deficiency and aging are suppressed by treatment with anti-resorptive agents (AR) or reversed with an anabolic agent, hPTH (1-34) (AA). Currently, patients with osteoporosis are often "cycled" through these different types of bone active agents for many years with little data to determine if sequential therapies for osteoporosis differentially affect bone strength and quality, or the durability if treatments are withdrawn. We recently reported that both a potent AR and an AA significantly improved trabecular bone mass and bone strength in estrogen deficient old rats compared to osteoporotic controls. However, there were differences between the two types of bone active agents, the AA had a greater increase in trabecular bone mass and whole bone strength than the AR;the potent AR had an overall higher and more consistent values for the localized material properties measured including elastic modulus and degree of bone mineralization (DBM) compared to the AA treated animals. Since these bone active agents augment bone strength by somewhat different mechanisms we hypothesize that in estrogen-deficient old rats: 1. Long-term treatment with potent ARs or an AA will improve localized bone quality and whole bone strength and withdrawal of ARs and an AA will differ in the time to reduction in bone quality and bone strength. 2. Altering the sequence of treatments will also differentially affect localized bone material properties and whole bone strength. To test these hypotheses we propose the following specific aims: 1. To determine the time frame for the deterioration of localized bone quality including the DBM, local microstructural bone tissue material properties, and whole bone strength differs after treatment with either ARs or an AA. 2. To determine if the localized aspects of bone quality including the DBM, local microstructural bone tissue material properties, and whole bone strength differ in estrogen deficient old rats treated sequentially with ARs followed by AA;AA followed by ARs or cyclic therapy with ARs, then AA or vehicle then AR, and ARs alone. 3. To determine if there is an association between the changes in biochemical markers and surface-based bone turnover, bone matrix composition, and localized and whole bone material properties with long term sequential therapies;ARs followed by AA;AA followed by ARs;or cyclic therapy with ARs, AA or vehicle and ARs alone. To accomplish these specific aims we will perform two very large experiments long-term studies using 10-month-old osteopenic rats. We will measure localized microstructural properties and whole bone strength and determine how the localized properties change with different treatment regimens, These preclinical studies will provide data that will guide clinicians in prescribing these bone active agents to maximize bone strength and the durability of their effects.
At least one third of women older than 65 years will experience an osteoporotic fracture. This research has direct relevance to public health by providing data that will guide clinicians in prescribing osteoporosis medication to maximize bone strength and the durability of their effects.
|Yao, Wei; Lane, Nancy E (2015) Targeted delivery of mesenchymal stem cells to the bone. Bone 70:62-5|
|Chaudhari, Abhijit J; Leahy, Richard M; Wise, Barton L et al. (2014) Global point signature for shape analysis of carpal bones. Phys Med Biol 59:961-73|
|Amugongo, Sarah K; Yao, Wei; Jia, Junjing et al. (2014) Effect of sequential treatments with alendronate, parathyroid hormone (1-34) and raloxifene on cortical bone mass and strength in ovariectomized rats. Bone 67:257-68|
|Amugongo, S K; Yao, W; Jia, J et al. (2014) Effects of sequential osteoporosis treatments on trabecular bone in adult rats with low bone mass. Osteoporos Int 25:1735-50|
|Yao, Wei; Guan, Min; Jia, Junjing et al. (2013) Reversing bone loss by directing mesenchymal stem cells to bone. Stem Cells 31:2003-14|
|Jia, Junjing; Yao, Wei; Amugongo, Sarah et al. (2013) Prolonged alendronate treatment prevents the decline in serum TGF-*1 levels and reduces cortical bone strength in long-term estrogen deficiency rat model. Bone 52:424-32|
|Baker-Lepain, Julie C; Lynch, John A; Parimi, Neeta et al. (2012) Variant alleles of the Wnt antagonist FRZB are determinants of hip shape and modify the relationship between hip shape and osteoarthritis. Arthritis Rheum 64:1457-65|
|Guan, Min; Yao, Wei; Liu, Ruiwu et al. (2012) Directing mesenchymal stem cells to bone to augment bone formation and increase bone mass. Nat Med 18:456-62|
|Shahnazari, Mohammad; Yao, Wei; Wang, Bob et al. (2011) Differential maintenance of cortical and cancellous bone strength following discontinuation of bone-active agents. J Bone Miner Res 26:569-81|
|Jia, Junjing; Yao, Wei; Guan, Min et al. (2011) Glucocorticoid dose determines osteocyte cell fate. FASEB J 25:3366-76|
Showing the most recent 10 out of 52 publications